A novel CX3CR1 antagonist eluting stent reduces stenosis by targeting inflammation

Mohammed T. Ali, Kenneth Martin, Arun H.S. Kumar, Erika Cavallin, Stefan Pierrou, Birgitta M. Gleeson, William L. McPheat, Elizebeth C. Turner, Chien-Ling Huang, Wisam Khider, Carl Vaughan, Noel M. Caplice

Research output: Journal article publicationJournal articleAcademic researchpeer-review

16 Citations (Scopus)


We evaluated the therapeutic efficacy of a novel drug eluting stent (DES) inhibiting inflammation and smooth muscle cell (SMC) proliferation. We identified CX3CR1 as a targetable receptor for prevention of monocyte adhesion and inflammation and in-stent neointimal hyperplasia without interfering with stent re-endothelization. Efficacy of AZ12201182 (AZ1220), a CX3CR1 antagonist was evaluated in inhibition of monocyte attachment in vitro. A prototype AZ1220 eluting PLGA-based polymer coated stent developed with an optimal elution profile and dose of 1 μM/stent was tested over 4 weeks in a porcine model of coronary artery stenting. Polymer coated stents without AZ1220 and bare metal stents were used as controls. AZ1220 inhibited monocyte attachment to CX3CL1 in a dose dependent manner. AZ1220 eluted from polymer coated stents in an ex vivo flow system retained bioactivity in inhibiting monocyte attachment to CX3CL1. At 4 weeks following deployment, AZ1220 eluting stents significantly reduced (~60%) in-stent stenosis compared to both bare metal and polymer only coated stents and markedly reduced peri-stent inflammation and monocyte/macrophage accumulation without affecting re-endothelization. Anti-CX3CR1 drug eluting stents potently inhibited in-stent stenosis and may offer an alternative to mTOR targeting by current DES, specifically inhibiting polymer-induced inflammatory response and SMC proliferation, while retaining an equivalent re-endothelization response to bare metal stents.
Original languageEnglish
Pages (from-to)22-29
Number of pages8
Publication statusPublished - 1 Jan 2015
Externally publishedYes


  • CX<inf>3</inf>CR1
  • Drug eluting stents
  • In-stent stenosis
  • Stent re-endothelization

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials


Dive into the research topics of 'A novel CX3CR1 antagonist eluting stent reduces stenosis by targeting inflammation'. Together they form a unique fingerprint.

Cite this